TY - JOUR
T1 - European multicenter evaluation of commercial enzyme immunoassays for detecting norovirus antigen in fecal samples
AU - Gray, Jim J.
AU - Kohli, Evelyne
AU - Ruggeri, Franco M.
AU - Vennema, Harry
AU - Sánchez-Fauquier, Alicia
AU - Schreier, Eckart
AU - Gallimore, Chris I.
AU - Iturriza-Gomara, Miren
AU - Giraudon, Helene
AU - Pothier, Pierre
AU - Di Bartolo, Ilaria
AU - Inglese, Nadia
AU - De Bruin, Erwin
AU - Van Der Veer, Bas
AU - Moreno, Silvia
AU - Montero, Vanessa
AU - De Llano, Marí C.
AU - Höhne, Marina
AU - Diedrich, Sabine M.
PY - 2007/10
Y1 - 2007/10
N2 - A total of 2,254 fecal samples were tested in a European multicenter evaluation of commercially available norovirus antigen detection assays. Two commercial enzyme immunoassays, IDEIA Norovirus (Oxoid; Thermo Fisher Scientific, Ely, United Kingdom) and RIDASCREEN Norovirus (R-Biopharm, Darmstadt, Germany), were included in the evaluation, and their performance was compared with the results of reverse transcription-PCR (RT-PCR). Included in the evaluation were samples collected in sporadic cases of gastroenteritis, samples from outbreaks in which two or more samples were collected, well-characterized samples representing genotypes currently cocirculating within Europe, and samples collected from patients with gastroenteritis caused by a pathogen other than norovirus. The sensitivities and specificities of the IDEIA Norovirus and RIDA-SCREEN Norovirus assays were 58.93 and 43.81% and 93.91 and 9637%, respectively, compared with RT-PCR. The sensitivities of both assays for outbreak investigations improved when six or more samples from an outbreak were examined. The IDEIA Norovirus assay exhibited reactivity to a broader range of norovirus genotypes than the RIDASCREEN Norovirus assay, which showed genotype-dependent sensitivities. The results indicate that, if used, these assays should serve as screening assays and the results should be confirmed by RT-PCR.
AB - A total of 2,254 fecal samples were tested in a European multicenter evaluation of commercially available norovirus antigen detection assays. Two commercial enzyme immunoassays, IDEIA Norovirus (Oxoid; Thermo Fisher Scientific, Ely, United Kingdom) and RIDASCREEN Norovirus (R-Biopharm, Darmstadt, Germany), were included in the evaluation, and their performance was compared with the results of reverse transcription-PCR (RT-PCR). Included in the evaluation were samples collected in sporadic cases of gastroenteritis, samples from outbreaks in which two or more samples were collected, well-characterized samples representing genotypes currently cocirculating within Europe, and samples collected from patients with gastroenteritis caused by a pathogen other than norovirus. The sensitivities and specificities of the IDEIA Norovirus and RIDA-SCREEN Norovirus assays were 58.93 and 43.81% and 93.91 and 9637%, respectively, compared with RT-PCR. The sensitivities of both assays for outbreak investigations improved when six or more samples from an outbreak were examined. The IDEIA Norovirus assay exhibited reactivity to a broader range of norovirus genotypes than the RIDASCREEN Norovirus assay, which showed genotype-dependent sensitivities. The results indicate that, if used, these assays should serve as screening assays and the results should be confirmed by RT-PCR.
UR - http://www.scopus.com/inward/record.url?scp=35548942716&partnerID=8YFLogxK
U2 - 10.1128/CVI.00214-07
DO - 10.1128/CVI.00214-07
M3 - Article
C2 - 17715333
AN - SCOPUS:35548942716
SN - 1556-6811
VL - 14
SP - 1349
EP - 1355
JO - Clinical and Vaccine Immunology
JF - Clinical and Vaccine Immunology
IS - 10
ER -